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Aims: To report preliminary data on baseline serum calcitonin concentrations and associated clinical characteristics in a global population with type 2
diabetes before liraglutide or placebo randomization.
Methods: The ongoing LEADER trial has enrolled 9340 people with type 2 diabetes and at high risk of cardiovascular disease at 410 centres worldwide.
People with baseline serum calcitonin ≤50 ng/l were randomized to liraglutide once daily or placebo and will be followed for up to 5 years. Serum
calcitonin was measured at baseline and will be measured annually thereafter. An independent committee of thyroid experts will oversee calcitonin
monitoring throughout the trial and will review all calcitonin concentrations ≥20 ng/l.
Results: The mean age of participants was 64.3± 7.2 years, 64.3% were men, and mean the body mass index was 32.5± 6.3 kg/m2. The median
(interquartile range) baseline serum calcitonin values were 3.9 (1.0 to >7.6) ng/l in men and 1.0 (1.0 to >1) ng/l in women. Serum calcitonin was>10 ng/l
in 14.6% of men and in 0.96% of women. In sex-specific multivariable linear analysis of covariance models, a reduced glomerular filtration rate (GFR)
was associated with higher serum calcitonin concentrations that were statistically significant. A 20ml/min/1.73m2 decrease in estimated GFR (eGFR)
was associated with a 14% increase in serum calcitonin in women and an 11% increase in men.
Conclusions: In the LEADER population, the prevalence of elevated serum calcitonin concentrations at baseline was high, and there was an inverse
association between eGFR and serum calcitonin concentrations.
Keywords: calcitonin, c-cell disease, diabetes, incretins
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Introduction
Liraglutide is a glucagon-like peptide 1 (GLP-1) analogue
approved for use in adults with type 2 diabetes mellitus [1,2].
In preclinical rodent studies, liraglutide and otherGLP-1 recep-
tor agonists were associated with hyperplasia of the calcitonin-
producing C-cells [C-cell hyperplasia (CCH)], C-cell adeno-
mas and C-cell carcinomas. C-cell pathology was absent in
liraglutide-treated GLP-1 receptor knockout animals [3,4],
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supporting a role for GLP-1 receptors in these pathological
findings. C-cell pathology did not develop in cynomolgusmon-
keys treated with liraglutide for>18months and at doses up to
64-fold greater than those calculated for human exposure [3].
In humans, long-term exposure to liraglutide does not
significantly affect serum calcitonin concentrations [5]. In
combined data from nine studies of ≥20weeks’ duration,
including>5000 subjects with either type 2 diabetes or obesity
without diabetes, there was no significant difference in the
proportion of subjects with calcitonin concentrations>20 ng/l
in the liraglutide versus the placebo groups [5]. Nonetheless,
based on non-clinical studies, labelling information in the
USA includes a boxed warning that liraglutide causes thyroid
C-cell tumours in rodents, and its use is contraindicated in
people with a personal or family history of medullary thyroid
carcinoma (MTC).
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The reference range of serum calcitonin is generally accepted
to be<10 ng/l [6]. Serum calcitonin is higher in healthy
men (<8.4 ng/l) than in healthy women (<5.0 ng/l). Serum
calcitonin >10 ng/l without known C-cell pathology has been
reported in people who consume tobacco and alcohol, as well
as in people with elevated serum gastrin levels, reduced kidney
function, autoimmune thyroid disease, sepsis, heterophilic
antibodies and with calcitonin production from non-MTC
malignancies [7].
In people with thyroid nodules, a serum calcitonin con-
centration >100 ng/l is generally associated with MTC;
concentrations between 10 and 100 ng/l are considered indeter-
minate and associated with C-cell pathology in only a minority
of subjects; a higher serum calcitonin concentration is asso-
ciated with a higher the likelihood of MTC [8]. In patients
with thyroid nodules, the sensitivity, specificity and positive
predictive values for detection of MTC depend on cut-off
values for serum calcitonin [9]. For these reasons the role of
serum calcitonin measurements in screening for MTC in the
thyroid nodule population is controversial, and uncertainty
is even greater concerning the specificity of indeterminate
calcitonin concentrations in people without known thyroid
abnormalities and with other medical conditions such as type 2
diabetes [10–14].
The Liraglutide Effect and Action in Diabetes: Evalua-
tion of Cardiovascular Outcome Results (LEADER) trial,
is an international, double-blind, placebo-controlled trial,
currently evaluating the cardiovascular safety of liraglutide
(www.clinicaltrials.gov NCT01179048). A total of 9340 peo-
ple with type 2 diabetes and at high risk of cardiovascular
events (with or without existing cardiovascular disease)
have been enrolled at 410 centres worldwide and ran-
domized 1 : 1 to liraglutide or placebo. Participants will be
followed for up to 5 years. To monitor any potential effects
of liraglutide on calcitonin concentrations, serum calcitonin
samples are collected at baseline and then at various time
points.
The present study is a preliminary report of baseline mea-
surements from the LEADER population. Specifically, we
report the baseline serum calcitonin concentrations in the
LEADER population, evaluate the influence of various clinical
characteristics on baseline calcitonin concentrations, and
describe the calcitonin monitoring programme developed for
the LEADER trial.
Materials and Methods
Study Design
The design of the LEADER trial has been described previously
[15]. People with type 2 diabetes and elevated cardiovascular
risk, who were either drug-naïve or treated with one or more
antihyperglycaemic drug (including basal and premix insulins)
were included. Initial exclusion criteria included basal calci-
tonin concentration >100 ng/l that was subsequently lowered
to≥50 ng/l, as requested by regulators in theUSA. Peoplewith a
personal or family history of multiple endocrine neoplasia type
2 or familial MTC were also excluded. As the target population
was at high risk of cardiovascular disease, we encouraged the
enrolment of people with reduced kidney function. We did not
exclude people usingmedication thought to increase serum cal-
citonin levels. Each enrolling centre’s institutional review board
approved the study.
Calcitonin Screening and Monitoring
Serumcalcitoninwasmeasured in the fasting state in all partici-
pants using a chemiluminescent immunometric assay (Siemens
Healthcare Diagnostics, Malvern, PA, USA) performed by a
central laboratory (ICONPLC,Dublin, Ireland). A serum calci-
tonin concentration of 2.0 ng/l was defined as the lower limit of
quantification (LLQ). For this particular assay, the upper limit
of normal (ULN) was defined as 8.4 ng/l for men and 5.0 ng/l
for women.
An independent calcitoninmonitoring committee (CMC) of
thyroid experts (L.H., R.M.T. and Steven Sherman, MD, Uni-
versity of Texas MD Anderson Cancer Center, Houston, TX,
USA) was appointed to oversee serum calcitonin monitoring
and to provide guidance for trial investigators. CMC clinicians
are not otherwise involved in the LEADER trial. Calcitonin
concentrations≥20 ng/l will be reported to the CMC for review
along with relevant supplementary data (demographics, dia-
betes history, concomitant medical history, concomitant medi-
cations, smoking status, supplemental laboratory tests, and rele-
vant adverse event data reported during the trial). Upon review
of all relevant materials, the CMC will provide recommen-
dations to the investigators for individual subjects, including
diagnostic procedures, treatment and continuation of the study
drug according to a pre-specified algorithm (Appendix). Fur-
thermore, both calcitonin concentrations ≥20 ng/l and diag-
noses of thyroid disease (whether related to the recommenda-
tions from the CMC or not) will be reported as medical events
of special interest.
After randomization, study visits occur at months 1, 3 and 6,
and every 6months thereafter until termination of the trial. Par-
ticipants will be followed for up to 5 years. During each study
visit, clinical events, study drug compliance and concomitant
medication usage are documented. Calcitonin concentrations
are measured annually.
Statistical Analysis
Serum calcitonin concentrations were not normally dis-
tributed, partly because of the substantial number of baseline
calcitonin values below the LLQ (87.3% of women, 27.8%
of men). The high prevalence of baseline calcitonin val-
ues<2.0 ng/l warranted the logarithmical transformation
before analysis, with all values<2.0 ng/l arbitrarily set as half
the LLQ value (2 ng/l) for descriptive purposes. Multivariable
linear analysis of covariance models were developed separately
formen andwomen because of themajor sex-dependent differ-
ences in the calcitonin distribution, with the log-transformed
calcitonin value as the dependent variable. Independent covari-
ates in the analysis of covariance models were prespecified and
included age, body mass index (BMI), smoking status, ethnic-
ity, diabetes, medical history, glycated haemoglobin, estimated
glomerular filtration rate (eGFR), autoimmune disease, thy-
roid disease (not otherwise specified), lipid concentrations and
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medication use (proton pump inhibitors, 𝛽-blocker agents,
H2 receptor antagonists and glucocorticoids). These variables
were selected before analysis by consideration of the potential
impact on calcitonin levels, based on an extensive review of the
literature and availability in the LEADER database. The effect
of each covariate on baseline calcitonin was first derived on
the log-calcitonin scale and then transformed back to obtain
a relative effect expressed as a percentage. All analyses were
performed using sas version 9.3 (SAS Institute, Cary, NC,
USA). Two-way interactions between the covariates eGFR
kidney function and BMI and thyroid disease and smoking
status (yes/no) as factors were evaluated in both gendermodels.
The main effects of all covariates/factors were retained in the
model, as the ample sample size of the LEADER study implied
no need for arbitrary variable selection.
Results
Baseline Demographics
The baseline demographic profile of the men, women and all
randomized LEADER trial participants (n= 9340) is shown in
Table 1. Of the 12 094 screened subjects, 2754 (23%) failed to
meet the inclusion criteria. Among the latter group, 42 subjects
(0.35% of the population screened) were excluded for having
calcitonin concentrations >50 ng/l. Because of the nature of
the study, no further information about these subjects is avail-
able. Two subjects with a calcitonin value of 115 ng/l were erro-
neously randomized. As soon as this error was discovered, trial
treatment was discontinued.
Serum Calcitonin
Baseline serum calcitonin concentrations were available for
6003 men and 3337 women. The distribution of serum calci-
tonin concentrations in study participants by sex is shown in
Figure 1 and Table 2. The median (interquartile range) base-
line serum calcitonin values were 3.9 (1.0 to >7.6) ng/l in men
and 1.0 (1.0 to >1) ng/l in women. Overall, 2.8% of women
and 21.3% of men had serum calcitonin concentrations above
their normal sex-specific reference values of 5.0 and 8.4 ng/l,
respectively. Sex was the most important determinant of ele-
vated serum calcitonin concentrations. Serum calcitonin con-
centrations in men were<2.0 ng/l (LLQ) in 27.8%, between 2.0
and 8.4 ng/l (ULN) in 50.3%, and>8.4 ng/l in 21.1%. Serumcal-
citonin concentrations in men were between >10 and ≤20 ng/l
in 7.3% and between >20 and <50 ng/l in 3.8%. In contrast,
87.3% of women had serum calcitonin concentrations below
2.0 ng/l (LLQ), 9.9% had calcitonin concentrations between
2.0 and 5.0 ng/l (ULN), and 2.8% had calcitonin concentra-
tions>5.0 ng/l. Only 0.75% of women had serum calcitonin
concentrations >10 and <20 ng/l and 0.2% had calcitonin con-
centrations>20 and ≤50 ng/l.
The relationships between baseline calcitonin concen-
trations, expressed in relation to the LLQ and sex-specific
ULN in men and women, and eGFR, BMI and smoking
are shown in Table 2. Among women, serum calcitonin
concentrations >10 ng/l were present in 0.9% with eGFR
60–89ml/min/1.73m2 (corresponding toThe National Kidney
Foundation – Kidney Disease Outcomes Quality Initiative
chronic kidney disease (CKD) stage 2), 1.7% with eGFR
30–59ml/min/1.73m2 (CKD stage 3), and 3.9% in women
with eGFR <30ml/min/1.73m2 (CKD stage 4 and 5). In men,
serum calcitonin concentrations >10 ng/l increased as eGFR
declined from normal (≥90ml/min/1.73m2) to eGFR values
corresponding to CKD stages 2, 3 and 4/5 (13.4, 14.9, 23.2
and 38.0%, respectively). Among participants with serum
calcitonin concentrations >10 ng/l, 21 of 32 women (65.6%)
and 678 of 979 men (69.3%) had an eGFR below normal
(<90ml/min/1.73m2).
Results of the log-linear multivariate models, by sex, are
shown in Figure 2A, B. In both men and women, eGFR, smok-
ing and higher BMI were clearly associated with higher serum
calcitonin concentrations. A 20-ml/min/1.73m2 decrease in
eGFR was associated with a 14% increase in serum calci-
tonin in women and an 11% increase in men. Smoking and
each 5-kg/m2 increase in BMI were associated with, respec-
tively, 21.9 and 11.1% increases in serum calcitonin in women,
and 16.3 and 9.9% increases in men. There was a statistically
significant association between absence of cardiovascular dis-
ease and calcitonin concentrations in men. In women there
was insufficient information to draw a conclusion (Figure 2B).
Two-way interactions between eGFR kidney function and BMI
as covariates and thyroid disease and current smoking status
(yes/no) were not identifiable (non-significant) for either gen-
der. Increasing age had a statistically significant negative corre-
lation with calcitonin concentrations in women but not inmen,
a finding of uncertain clinical significance and mechanism.
Discussion
This present report, in which the baseline calcitonin concentra-
tions in a global high cardiovascular risk type 2 diabetes popu-
lation [15] were analysed, is believed to be the largest study of
baseline calcitonin concentrations in a population not specif-
ically selected for the presence of thyroid nodules. In the thy-
roid nodule population, a calcitonin concentration >10 ng/l is
often regarded as a threshold above which pathological C-cell
disorders should be investigated [8]. In our LEADER trial pop-
ulation, 10.8% of participants had serum calcitonin concen-
trations >10 ng/l, and 2.6% had concentrations>20 ng/l. We
analysed several possible explanations for the elevated calci-
tonin concentration in this population. Because of the nature
of the baseline information and because the effect of liraglu-
tide on calcitonin is subject to ongoing monitoring throughout
the trial, information concerning baseline thyroid palpation,
thyroid ultrasonography and thyroid pathology is not avail-
able in this population, nor are follow-up data available for
patients excluded for having baseline calcitonin concentra-
tions>50 ng/l.
The maximum C-cell surface area in the adult thyroid
gland is twice as high in men as in women [16], which
could account for the differences in baseline and stimu-
lated calcitonin in men compared with women [7]. In the
present study, sex was highly determinative of elevated cal-
citonin concentrations: >21% of men and nearly 3% of
women had serum calcitonin concentrations above their
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Table 1. Baseline demographic characteristics of the study participants.
Total (n= 9340) Female (n= 3337) Male (n= 6003)
Age, years
Mean± s.d. 64.3± 7.2 64.4± 7.2 64.2± 7.3
Median 64.0 64.0 64.0
Body weight, kg
Mean± s.d. 91.8± 21.0 84.7± 19.5 95.7± 20.8
Median 89.9 82.4 93.2
Body mass index, kg/m2
Mean± s.d. 32.5± 6.3 33.6± 6.8 31.9± 5.9
Median 31.7 32.8 31.2
HbA1c, %
Mean± s.d. 8.7± 1.5 8.8± 1.6 8.6± 1.5
Median 8.3 8.4 8.2
Diabetes duration, years
Mean± s.d. 12.7± 8.0 13.3± 8.3 12.4± 7.8
Median 11.3 11.8 11.1
Blood pressure, mmHg
Systolic
Mean± s.d. 137.7± 18.6 139.1± 19.2 136.9± 18.2
Median 137.0 138.0 136.0
Diastolic
Mean± s.d. 77.9± 10.5 78.1± 10.7 77.8± 10.3
Median 78.5 79.0 78.5
Heart rate, beats per min
Mean± s.d. 73.2± 11.4 74.4± 10.9 72.5± 11.6
Median 72.0 74.0 72.0
eGFR, n (%)
≥90ml/min/1.73m2 3447 (36.9) 1207 (36.2) 2240 (37.3)
60–89ml/min/1.73m2 3860 (41.3) 1353 (40.5) 2507 (41.8)
30–59ml/min/1.73m2 1854 (19.9) 700 (21.0) 1154 (19.2)
<30ml/min/1.73m2 177 (1.9) 76 (2.3) 101 (1.7)
Glucose-lowering treatment, n (%)
Diet or no treatment 504 (5.4) 128 (5.3) 376 (5.5)
Insulin 665 (7.1) 279 (8.4) 386 (6.4)
Oral glucose-lowering* 4931 (52.8) 1687 (50.6) 3244 (54.0)
Oral glucose-lowering+ insulin 3240 (34.7) 1195 (35.8) 2045 (34.1)
Prior cardiovascular disease, n (%) 7592 (81.3) 2544 (76.2) 5048 (84.1)
Number of oral antihyperglycaemic medications used
1 1917 (20.5) 679 (20.3) 1238 (20.6)
2 2686 (28.8) 914 (27.4) 1772 (29.5)
>2 328 (3.5) 94 (2.8) 234 (3.9)
Yes 7592 (81.3) 2594 (76.2) 5048 (84.1)
No 1748 (18.7) 793 (23.8) 955 (15.9)
Smoking, n (%)
Current 1130 (12.1) 281 (8.4) 849 (14.1)
Previous 4337 (46.4) 926 (27.7) 3411 (56.8)
Never 3873 (41.5) 2130 (63.8) 1743 (29.0)
Proton pump inhibitor use, n (%) 1963 (21.0) 753 (22.6) 1210 (20.2)
H2 receptor antagonist use, n (%) 303 (3.2) 106 (3.2) 197 (3.3)
BMI, body mass index; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; s.d., standard deviation.
*Not used in combination with insulin.
sex-specific normal reference values of 8.4 and 5.0 ng/l,
respectively. Differences between men and women persisted
at the higher serum calcitonin thresholds of 10 ng/l (16.3 vs
0.96%, respectively) and 20 ng/l (4.0 vs 0.21%, respectively).
As a consequence of our inclusion criteria, two-thirds of our
participants had an eGFR<90ml/min/1.73m2 at baseline [15].
We found a significant inverse association between baseline
serum calcitonin concentration and eGFR in both men and
women, similarly to other investigators. Lissak et al. [17],
reported significantly higher basal calcitonin concentrations
(p< 0.05) in 30 subjects with moderately reduced kidney
function (eGFR<58ml/min) compared with controls (3.55
vs 2.00 ng/l). Specifically, 20% had basal calcitonin >10 ng/l
(maximum: 51 ng/l), including six out of 18 men and none
out of 12 women. Kanbay et al. [18] reported mean serum
calcitonin concentrations of 11.5± 7.8 ng/l in a population
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Figure 1. Distribution of calcitonin measurements by sex. The lower limit
of quantification (LLQ) for both men and women was 2.0 ng/l. The upper
limit of normal was 5.0 ng/l for women and 8.4 ng/l for men.
of 88 subjects with moderately-to-mildly reduced kidney
function (eGFR 46–87ml/min/1.73m2). Niccoli et al. [19]
studied 154 people undergoing haemodialysis and found basal
calcitonin concentrations >20 ng/l in 25.3% and >90 ng/l in
7.8%. Akan et al. [20] studied 283 people undergoing dialysis
and found median calcitonin concentrations of 12 ng/l in men
and 2 ng/l in women, while 58% ofmen and 10% of women had
concentrations >10 ng/l.
In women, the prevalence of a serum calcitonin concen-
tration >10 ng/l was similar across eGFR categories (eGFR
≥90ml/min/1.73m2: 0.9%; eGFR 60–89ml/min/1.73m2:
1.0%; eGFR 30–59ml/min/1.73m2: 0.7%; and eGFR
<30ml/min/1.73m2: 3.9%). In men, the prevalence of a serum
calcitonin concentration >10 ng/l increased with declining
eGFR, from 13.4% for men with eGFR ≥90ml/min/1.73m2,
14.9% for those with eGFR 60–89ml/min/1.73m2, 23.2% for
those with eGFR 30–59ml/min/1.73m2 to 38.0% for those
with eGFR <30ml/min/1.73m2. In people with serum calci-
tonin concentrations >10 ng/l, 21 of 32 women (65.6%) and
678 of 978 men (69.3%) had an eGFR <90ml/min/1.73m2.
In most studies the ULN for serum calcitonin is higher in
smokers than in non-smokers [21], but the mechanism for this
difference is unknown. In the present study, 1.8% of women
who smoked had serum calcitonin concentrations >10 ng/l,
twice the rate of female non-smokers (0.9%). In men, these
figures were 19.2% for smokers and 15.7% for non-smokers,
respectively. Among participants with serum calcitonin con-
centrations >10 ng/l, 5 out of 27 (18.5%) women and 163 out
of 978 (16.7%) men were current smokers.
In multivariable analysis performed separately for men and
women, factors common to both sexes that were associated
with statistically significant changes in serum calcitonin con-
centrations were reduced eGFR, smoking, increased BMI,
and presence of thyroid disease, but not use of proton pump
inhibitors. There was an inverse relationship between serum
calcitonin and both eGFR and presence of thyroid disease,
and a direct relationship between serum calcitonin and both
BMI and smoking. Serum calcitonin concentration has been
reported to be higher when serum gastrin is elevated, including
individuals with pernicious anaemia, intake of drugs inhibiting
gastric acid secretion, or gastrinomas. In work by Erdogan
et al. [22], individuals taking proton pump inhibitors or H2
blockers had a mean serum calcitonin of 11.9 ng/l, whereas
the concentration was 6.0 ng/l in those not taking these agents.
We found no association between serum calcitonin and H2
receptor antagonist or proton pump inhibitor use. Although
the explanation for our lack of correlation is uncertain, it might
be attributable to reporting bias in that non-prescription use
of these agents was not recorded. Information on the types of
thyroid disease was not collected as part of the trial, and more
detailed baseline information is not available. It is possible
that the lower calcitonin concentrations might be related to
previous thyroidectomy.
Food intake has been reported to elevate serum calcitonin
concentration [23], but we measured serum calcitonin concen-
trations in the fasting state. Heterophilic antibodies may falsely
elevate serum calcitonin concentrations in up to 1.3% of the
population [24], however, these were not assessed in the present
study. Other potential factors leading to elevated serum calci-
tonin concentrations unrelated to C-cell pathology include cal-
citonin production from non-MTCmalignancies, autoimmune
thyroid disease, alcohol consumption and sepsis [7]. Previous
studies have not confirmed an association between autoim-
mune thyroid disease and elevated serum calcitonin concentra-
tions [25]. The present study did not find a significant associa-
tion between autoimmune thyroid disease and serumcalcitonin
concentrations; however, there was no systematic effort to iden-
tify autoimmune thyroid disease. A calcitonin concentration
>10 ng/l is often regarded as a threshold above which patholog-
ical C-cell disorders should be investigated [8]. For this reason,
it is important to compare the present study with several other
population studies. Only 25 of 5000 (0.5%) people with type 2
diabetesmellitus whowere enrolled in previous trials of liraglu-
tide had a baseline serum calcitonin concentration >20 ng/l
[5]. Costante et al. [8] studied 5817 subjects with thyroid nod-
ules, a population thought to have a high prevalence of MTC,
and found that only 5% had a serum calcitonin concentration
>10 ng/l. d’Herbomez et al. [7] measured serum calcitonin in
375 clinically euthyroid subjects using five different calcitonin
assays and found 2.5–9.8% had serum calcitonin concentra-
tions >10 ng/l, most of whom were male smokers, although
there was considerable variability between assays used.
In the present study, 64% of participants weremen compared
with only 19% in the study by Costante et al. [8]. Although
there was a statistically significant association between smok-
ing status and serum calcitonin in both men and women,
it is unlikely that smoking alone accounts for the differences
between the present study and others. It is unlikely that the par-
ticular calcitonin assay used in the present study explains the
higher prevalence of elevated serum calcitonin concentrations,
given that 95% of normal healthy people tested with this assay
have serum calcitonin concentrations≤8.4 ng/l for men and
≤5.0 ng/l for women. It is likely that our high-risk population
included a higher prevalence of subjects with elevated BMI.
Screening calcitonin studies in thyroid nodule populations
have typically not reported BMI data.
For the present study, we intentionally selected a popula-
tion with type 2 diabetes at high risk of cardiovascular events.
The reported higher proportion of both men and women with
Volume 17 No. 5 May 2015 doi:10.1111/dom.12444 481
original article DIABETES, OBESITY AND METABOLISM
Table 2. Distribution of baseline calcitonin values stratified by sex and clinically relevant risk factors.
Women*
Calcitonin (ng/l)
≤2.0 (n= 2911)
>2.0 to ≤5.0
(n= 329)
>5.0 to ≤10.0
(n= 61)
>10.0 to ≤20.0
(n= 25)
>20.0 to ≤50.0
(n= 7)
eGFR, ml/min/1.73m2
≥90 1091 (90.5) 87 (7.2) 17 (1.4) 10 (0.8) 1 (0.1)
60–89 1195 (88.5) 119 (8.8) 23 (1.7) 9 (0.7) 4 (0.3)
30–59 570 (81.4) 105 (15.0) 20 (2.9) 4 (0.6) 1 (0.1)
<30 54 (71.1) 18 (23.7) 1 (1.3) 2 (2.6) 1 (1.3)
BMI, kg/m2
<25 kg/m2 357 (92.5) 24 (6.2) 3 (0.8) 0 2 (0.5)
25–30 kg/m2 791 (90.2) 69 (7.9) 7 (0.8) 9 (1.0) 1 (0.1)
30–35 kg/m2 855 (86.0) 113 (11.4) 17 (1.7) 8 (0.8) 1 (0.1)
>35 kg/m2 902 (84.3) 123 (11.5) 34 (3.2) 8 (0.7) 3 (0.3)
Current smoking
No 2676 (87.7) 296 (9.7) 53 (1.7) 22 (0.7) 5 (0.2)
Yes 235 (83.6) 33 (11.7) 8 (2.8) 3 (1.1) 2 (0.7)
Cardiovascular disease
Age ≤60 years 761 (84.6) 103 (11.5) 22 (2.4) 10 (1.1) 3 (0.3)
Age>60 years 1430 (87.0) 168 (10.2) 32 (1.9) 10 (0.6) 3 (0.2)
Thyroid disease 730 (89.6) 59 (7.2) 13 (1.6) 11 (1.3) 2 (0.2)
Men†
Calcitonin (ng/l)
≤2.0
(n= 1669)
>2.0 to ≤8.4
(n= 3048)
>8.4 to ≤10.0
(n= 301)
>10.0 to ≤20.0
(n= 738)
>20.0 to ≤50.0
(n= 230)
>50.0 to ≤100.0
(n= 8)
>100.0
(n= 2)
eGFR
≥90ml/min/1.73m2 732 (32.7) 1104 (49.3) 103 (4.6) 234 (10.5) 62 (2.8) 4 (0.2) 0
60–89ml/min/1.73m2 685 (27.4) 1318 (52.7) 127 (5.1) 301 (12.0) 68 (2.7) 3 (0.1) 0
30–59ml/min/1.73m2 240 (20.8) 578 (50.1) 68 (5.9) 181 (15.7) 84 (7.3) 1 (0.1) 2 (0.2)
<30ml/min/1.73m2 11 (11.0) 48 (48.0) 3 (3.0) 22 (22.0) 16 (16.0) 0 0
BMI
<25 kg/m2 270 (31.7) 44 (52.4) 29 (3.4) 91 (10.7) 16 (1.9) 0 0
25–30 kg/m2 584 (28.6) 1077 (52.8) 92 (4.5) 220 (10.8) 66 (3.2) 2 (0.1) 0
30–35 kg/m2 503 (27.3) 926 (50.3) 95 (5.2) 237 (12.9) 77 (4.2) 2 (0.1) 1 (0.1)
>35 kg/m2 312 (24.8) 594 (47.3) 85 (6.8) 190 (15.1) 71 (5.6) 4 (0.3) 1 (0.1)
Current smoking
No 1452 (28.2) 51.0 (253) 253 (4.9) 619 (12.0) 188 (3.7) 6 (0.1) 2 (0.0)
Yes 217 (25.6) 49.5 (58.0) 48 (5.7) 119 (14.0) 42 (5.0) 2 (0.2) 0
Cardiovascular disease
Age≤60 years 514 (29.1) 870 (49.2) 87 (4.9) 224 (12.7) 67 (3.8) 5 (0.3) 2 (0.1)
Age>60 years 858 (26.2) 1705 (52.1) 164 (5.0) 413 (12.6) 130 (4.0) 3 (0.1) 0
Thyroid disease 207 (39.3) 215 (40.8) 18 (3.4) 63 (12.0) 21 (4.0) 2 (0.4) 1 (0.2)
BMI, body mass index; eGFR, estimated glomerular filtration rate.
Data are n (%).
*Lower limit of quantification= 2.0 ng/l; upper limit of normal= 5.0 ng/l.
†Lower limit of quantification= 2.0 ng/l; upper limit of normal= 8.4 ng/l.
calcitonin concentrations above the ULN in the present study
is probably related to the specific population under investiga-
tion. The present study also had a greater proportion of men,
a higher prevalence of current smokers and a high mean BMI,
as well as other unknown factors that could potentially affect
calcitonin levels; however, in the absence of clinical correla-
tions, we cannot completely exclude an increased prevalence of
C-cell pathology in the present population.
In the general population, an elevated serum calcitonin level
is a sensitive biomarker for pathological diseases of the C cells,
MTC and CCH. Given the high prevalence of elevated serum
calcitonin concentrations in the present study it is important
to consider the specificity of serum calcitonin concentrations
between 10 and 100 ng/l for MTC or CCH. In a study of 5817
subjects with thyroid nodules, a population thought to be at
higher risk ofMTC than the general population, 216 (3.7%) had
a serum calcitonin concentration between >10 and ≤20 ng/l
[8]. Only 1 patient eventually had surgery because of rising
serum calcitonin concentration, and CCH was found. There
were 49 subjects (0.84%) with serum calcitonin concentrations
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Figure 2. Forest plots showing the results of multivariate log-linear analysis of calcitonin concentrations in (A) men and (B) women. For each explanatory
variable, the relative effect (1 is the neutral value) is depicted together with the corresponding 95% confidence interval. The right panel cites the numbers
together with the p value derived from the test of ‘no difference’. HbA1c, glycated haemoglobin; eGFR, estimated glomerular filtration rate; CVD,
cardiovascular disease.
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between >20 and <50 ng/l. Of these, 12 had abnormal penta-
gastrin stimulation tests and 10 agreed to surgery; 4 of these
subjects hadMTC, and 4 had CCH. All nine subjects with basal
calcitonin>100 ng/l had MTC. These findings indicate that
only a small percentage of individuals with thyroid nodules
and serum calcitonin concentrations between 10 and <50 ng/l
will have MTC. Based on our observations, serum calcitonin
concentrations between 20 and 50 ng/l may have even lower
specificity for C-cell disease in men with type 2 diabetes at
high risk of atherosclerotic disease, such as that in the present
patient population. For this baseline assessment of the LEADER
population, we do not have additional information about thy-
roid investigations in any of these subjects. Information
about subjects with persistent serum calcitonin concentra-
tions>20 ng/l will be collected and will be the subject of future
publications.
In summary, the LEADER trial population had a higher
than anticipated prevalence of elevated serum calcitonin
concentrations. The population was obese (mean BMI
32.5 kg/m2), and nearly 25% of participants had reductions in
eGFR<60ml/min/1.73m2. Lower eGFR and higher BMI had
a significant association with serum calcitonin concentrations.
Other factors probably contributing to the distribution of
calcitonin concentrations in the present study were the high
prevalence of men and smokers. Further studies are needed to
determine the serum calcitonin threshold that should trigger a
search for C-cell pathology in a population such as the present
one, particularly in light of the additional 42 subjects with
serum calcitonin concentrations>50 ng/l excluded before our
study (0.35% of subjects screened). Notably, a thyroid nodule
population thought to be at higher risk of C-cell disorders [6]
found 17 patients (0.29%) with a basal calcitonin≥50 ng/l;
therefore, the reference range for serum calcitonin concen-
trations in the normal population may not be applicable
to subjects with cardiovascular disease and type 2 diabetes
mellitus.
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Appendix
Algorithm for calcitonin screening and
monitoring
• Calcitonin ≥50 ng/l
- A calcitonin measurement >50 ng/l is a screening failure,
and the patient shall be referred to a thyroid specialist for
further evaluation.
• Calcitonin <20 ng/l
- Investigator shall evaluate factors potentially leading to
calcitonin elevation.
- Calcitonin sampling shall be performed at intervals indi-
cated in the study protocol with no further action unless
levels rise to ≥20 ng/l.
- If the value is the last one taken in the trial, the subject shall
be referred to a thyroid specialist for further evaluation.
• Calcitonin ≥20 and <50 ng/l
- Calcitonin sampling shall be performed at intervals indi-
cated in the study protocol with no further action unless
levels rise to≥50 ng/l.
- No impact on continuation of trial treatment.
- If the value is the last one taken in the trial, the subject shall
be referred to a thyroid specialist for further evaluation.
• Calcitonin ≥50 and <100 ng/l
- The subject shall be referred to a thyroid specialist for
further evaluation.
- Recommendations about a diagnostic evaluation shall
include ultrasound examination and, if available and not
contraindicated, a pentagastrin stimulation test (Europe).
Subjects with positive pentagastrin stimulation tests will be
considered for surgery. In the US, where pentagastrin is
not available, thyroid ultrasound and fine needle aspiration
biopsy may add important clinical information informing
the need for surgery.
- If calcitonin levels fluctuate around 50 ng/l without demon-
strating a progressive rise, then subjects may continue on the
drug.
- If calcitonin level is confirmed to be above 50 ng/l, then
the CMC shall recommend the study investigator remove
the subject from study treatment. Study treatment may
be re-introduced if the reason for discontinuation no
longer exists (e.g., suspicion of potential C-cell disease is
excluded).
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• Calcitonin ≥100 ng/l
- The subject shall be referred to a thyroid specialist for
further evaluation.
- Recommendations about a diagnostic evaluation shall
include ultrasound examination and, if available and not
contraindicated, a pentagastrin stimulation test (Europe).
Subjects with positive pentagastrin stimulation tests will be
considered for surgery. In the US, where pentagastrin is
not available, thyroid ultrasound and fine needle aspiration
biopsy may add important clinical information informing
the need for surgery.
- If C-cell neoplasia is diagnosed, family history of MTC
or multiple endocrine neoplasia type 2 will be evoked, and
a RET protooncogene analysis should be undertaken. The
CMC shall provide recommendations to the investigator
regarding interpretation of genetic test results.
- If calcitonin level rises above 100 ng/l, then the CMC shall
recommend the study investigator remove the subject from
study treatment.
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